相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Peptide Blocking CTLA-4 and B7-1 Interaction
Stepan V. Podlesnykh et al.
MOLECULES (2021)
Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab
Xiaoling Shang et al.
LUNG CANCER (2021)
TMB or not TMB as a biomarker: That is the question
Alfredo Addeo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
Marcelo Negrao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
Meichen Gu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis
Letizia Gianoncelli et al.
ANTICANCER RESEARCH (2020)
CTLA-4: From mechanism to autoimmune therapy
Arezoo Hosseini et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Targeting the MAPK Pathway in KRAS-Driven Tumors
Matthias Drosten et al.
CANCER CELL (2020)
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy
Kaiyan Chen et al.
LUNG CANCER (2020)
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
Wolfgang M. Brueckl et al.
BMC CANCER (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer
Corrin A. Wohlhieter et al.
CELL REPORTS (2020)
A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer
Xiangkun Wu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer
Yixin Zhou et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition
Qiong Lyu et al.
CANCER CONTROL (2020)
Targeting the untargetable KRAS in cancer therapy
Pingyu Liu et al.
ACTA PHARMACEUTICA SINICA B (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
Sandra Assoun et al.
LUNG CANCER (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
E. E. Vokes et al.
ANNALS OF ONCOLOGY (2018)
ClinicalandPathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC)
Rieke Frank et al.
CLINICAL CANCER RESEARCH (2018)
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Scott J. Rodig et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
Mirjana Efremova et al.
NATURE COMMUNICATIONS (2018)
Patterns of mutations in TP53 mutated AML
John S. Welch
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
Francesco Facchinetti et al.
LUNG CANCER (2017)
Review on EGFR Inhibitors: Critical Updates
Davinder Singh et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)
Classification and characterization of microsatellite instability across 18 cancer types
Ronald J. Hanse et al.
NATURE MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting RAS-mutant Cancers: Is ERK the Key?
Meagan B. Ryan et al.
TRENDS IN CANCER (2015)
TP53 Mutations in Nonsmall Cell Lung Cancer
Akira Mogi et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
David B. Shackelford et al.
NATURE REVIEWS CANCER (2009)
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers
GP Pfeifer et al.
ONCOGENE (2002)
分享论文
